Parathyroid hormone for the treatment of osteoporosis

Obstetrical and Gynecological Survey

Volumn 59, Issue 12, 2004, Pages 826-832

  McClung, Michael ^a,b  

^a OREGON OSTEOPOROSIS CENTER   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; FLUORIDE; GLUCOCORTICOID; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM; STRONTIUM RENELATE; UNCLASSIFIED DRUG;

BONE CANCER; BONE DENSITY; BONE FRAGILITY; BONE MASS; BONE METABOLISM; BONE TUMOR; CARCINOGENICITY; CELL ACTIVITY; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ESOPHAGUS INJURY; ESTROGEN DEFICIENCY; FRACTURE; FRACTURE REDUCTION; HORMONAL THERAPY; HORMONE ACTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; INJECTION SITE; LEG CRAMP; NAUSEA; NEPHROLITHIASIS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT MONITORING; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

FEMALE; HUMANS; MALE; OSTEOPOROSIS; PARATHYROID HORMONE; TERIPARATIDE;

EID: 9344220503     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ogx.0000146584.12831.c9     Document Type: Review

References (39)

1. National Institute of Health. Osteoporosis prevention, diagnosis and therapy. NIH Consensus Statement 2000;17:1-45.
2. Chrischilles EA, Butler CD, Davis CS, et al. A model of lifetime osteoporosis impact. Arch Intern Med 1991;151:2026-2032.
3. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359:1841-1850.
4. Gamero P. Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 2000;11:55-65.
5. Delmas P. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-2036.
6. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
7. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study (PROOF Study). Am J Med 2000;109:267-276.
8. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637-645.
9. Liberman UA, Weiss SR, Broil JL, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-1443.
10. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541.
11. Harris S, Watts N, Genant H, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. N Engl J Med 1999;282: 1344-1352.
12. Reginster J-Y, Minne H, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
13. Black DM, Thompson DE, Bauer DC et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 2000;85: 4118-4124.
14. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;334:333-340.
15. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-809.
16. Baum HB, Biller BM, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996;125:883-890.
17. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with post-menopausal osteoporosis. N Engl J Med 2004;350:459-468.
18. Bauer W, Aub AC, Albright F. Studies of calcium and phosphorus metabolism. V. A study of the bone trabeculae as a readily available reserve of calcium. J Exp Med 1929;49:145-161.
19. Tam CS, Heersche JNM, Murray TM, et al. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 1982;110:506-512.
20. Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997;138:4607-4612.
21. Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439-446.
22. Rubin MR, Cosman F, Lindsay R, et al. The anabolic effects of parathyroid hormone. Osteoporos Int 2002;13:267-277.
23. Reeve J, Meunier PJ, Parsons JA, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. BMJ 1980;280:1340-1344.
24. Slovik DM, Rosenthal DI, Doppelt SH, et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1986;1:377-381.
25. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.
26. Zanchetta JR, Bogado CE, Ferretti JL, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:539-543.
27. Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932-1941.
28. Tashjian AH Jr, Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002;17:1151-1161.
29. Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol 2003;88:5212-5220.
30. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-555.
31. Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001;6:925-931.
32. Hodsman AB, Steer BM, Fraher LJ, et al. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner 1991;14:67-83.
33. Black DM, Greanspan SL, Ensrud KE, et al. PaTH Study Investigators: the effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-1215.
34. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-1226.
35. Ettinger B, San Martin J, Crans GG, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alehdronate. J Bone Miner Res 2004;19:745-751.
36. Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85:3069-3076.
37. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17.
38. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998;102:1627-1633.
39. Rittmaster R, Bolognese M, Ettinger M, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129-2134.